Search research articles
Contact Us
Filters
Showing results (211-220 of 231) with videos related to
Page
of 24
Sort By:
Cancer Discovery
|
October 20, 2023
Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study
William K Kelly, Daniel C Danila, Chia-Chi Lin, et al.
The Oncologist
|
May 10, 2020
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
Ching-Yao Yang, Wei-Yu Liao, Chao-Chi Ho, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 22, 2012
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial
David C Smith, Matthew R Smith, Christopher Sweeney, et al.
British Journal of Cancer
|
March 13, 2020
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours
Johann de Bono, Chia-Chi Lin, Li-Tzong Chen, et al.
Journal for Immunotherapy of Cancer
|
January 21, 2022
Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study
Paolo Andrea Zucali, Chia-Chi Lin, Bradley C Carthon, et al.
Journal for Immunotherapy of Cancer
|
June 17, 2020
Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors
Jayesh Desai, Sanjeev Deva, Jong Seok Lee, et al.
JTO Clinical and Research Reports
|
May 24, 2023
Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced <i>ALK</i>-Positive NSCLC
Qing Zhou, Ross A Soo, Gee-Chen Chang, et al.
The Lancet. Oncology
|
November 11, 2018
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
Benjamin J Solomon, Benjamin Besse, Todd M Bauer, et al.
The Oncologist
|
April 24, 2025
Barriers to publishing early phase clinical trials: the oncologists' perspective
Merel J J Lucassen, Pedro Bergmann, Olga Husson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 4, 2021
Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia
Eytan M Stein, Daniel J DeAngelo, Jörg Chromik, et al.
Page
of 24
Search research articles
Search
Showing results (211-220 of 231) with videos related to
Sort By:
Page
of 24
Cancer Discovery
|
October 20, 2023
Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study
William K Kelly, Daniel C Danila, Chia-Chi Lin, et al.
The Oncologist
|
May 10, 2020
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
Ching-Yao Yang, Wei-Yu Liao, Chao-Chi Ho, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 22, 2012
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial
David C Smith, Matthew R Smith, Christopher Sweeney, et al.
British Journal of Cancer
|
March 13, 2020
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours
Johann de Bono, Chia-Chi Lin, Li-Tzong Chen, et al.
Journal for Immunotherapy of Cancer
|
January 21, 2022
Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study
Paolo Andrea Zucali, Chia-Chi Lin, Bradley C Carthon, et al.
Journal for Immunotherapy of Cancer
|
June 17, 2020
Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors
Jayesh Desai, Sanjeev Deva, Jong Seok Lee, et al.
JTO Clinical and Research Reports
|
May 24, 2023
Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced <i>ALK</i>-Positive NSCLC
Qing Zhou, Ross A Soo, Gee-Chen Chang, et al.
The Lancet. Oncology
|
November 11, 2018
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
Benjamin J Solomon, Benjamin Besse, Todd M Bauer, et al.
The Oncologist
|
April 24, 2025
Barriers to publishing early phase clinical trials: the oncologists' perspective
Merel J J Lucassen, Pedro Bergmann, Olga Husson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 4, 2021
Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia
Eytan M Stein, Daniel J DeAngelo, Jörg Chromik, et al.
Page
of 24